Figure 3—figure supplement 1

(A) Total blastoderm explant area prior and from shield stage onwards (−60 min: n = 24, N = 3; 0 min: n = 23, N = 3; 30 min: n = 23, N = 3; 60 min: n = 22, N = 3; 90 min: n = 21, N = 3; 120 min: n = 22, N = 3; 150 min: n = 23, N = 3; 180 min: n = 22, N = 3; 210 min: n = 23, N = 3). (B) Width of the round portion of blastoderm explants from shield stage onwards (90 min: n = 20, N = 3; 120 min: n = 22, N = 3; 150 min: n = 23, N = 3; 180 min: n = 22, N = 3; 210 min: n = 23, N = 3). (C) Length of the explant extension from shield stage onwards (90 min: n = 20, N = 3; 120 min: n = 22, N = 3; 150 min: n = 23, N = 3; 180 min: n = 22, N = 3; 210 min: n = 23, N = 3). Time in min. Schematic representation of the quantification method is shown at the top (A-C). (D) Bright-field single-plane images DMSO or HUA-treated blastoderm explants (treated from shield to bud stage; DMSO: n = 29, N = 3; HUA: n = 35, N = 3) at bud stage. Scale bar: 200 µm. (E) Percentage of extended or not-extended DMSO or HUA-treated blastoderm explants (treated from shield to bud stage; DMSO: n = 28, N = 3; HUA: n = 34, N = 3) at bud stage. (F) Normalized extension length of extended DMSO or HUA-treated blastoderm explants (treated from shield to bud stage; DMSO: n = 28, N = 3; HUA: n = 32, N = 3) at bud stage. ns, not significant (Unpaired t test).

Figure 3—figure supplement 1—source data 1.